Tumor antigens for determining cancer therapy

US10188712B2 · kind B2 · utility

Assignees

• BioNTech AG · DE
• TRON—Translationale Onkologie an der Universitätsmedizin Mainz Gemeinnützige GmbH · DE

Inventors

• Ugur Sahin · Mainz, DE
• Claudia Paret · Mainz, DE
• Kirsten Vormbrock · Mainz, DE
• Christian Bender · Mainz, DE
• Petra Simon · Mainz, DE
• Christoph Hartmann · Frankfurt, DE
• Stefanie Hubich · Mainz, DE
• Thomas Bukur · Mainz, DE
• Thorsten Litzenberger · Olsbrücken, DE

Key dates

• Filing date: Jul 30, 2014
• Grant date: Jan 29, 2019
• Expiry date: Jul 30, 2034

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/47
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.